Xuantai Pharmaceutical (688247.SH): Posaconazole enteric tablets passed EU DCP approval

Zhitong Finance App News, Xuantai Pharmaceutical (688247.SH) issued an announcement. Recently, the company received reference to the EU Decentralized Approval Procedure (DCP) approval documents issued by the Dutch (NL) Drug Evaluation Committee. The company's product posaconazole enteric tablets passed the EU DCP approval and obtained marketing permits in the Netherlands, Germany, Spain, France and Italy.

According to reports, posaconazole enteric tablets are mainly used to treat aggressive aspergillus or candida infections. Posaconazole is a second-generation triazole antifungal drug derived from itraconazole. It works by inhibiting ergosterol synthesis to treat aggressive aspergillus or candida infections, and is currently one of the commonly used anti-invasive fungal infections in clinical practice. Posaconazole is highly safe, has no obvious hepatic and nephrotoxicity, and is well tolerated. It can be used in patients requiring long-term treatment. It is superior to similar drugs such as fluconazole or itraconazole in preventing deep fungal infections in immunodeficiency patients.